Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:5.99.1.3 (
topoisomerase
)
9,911
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The vaccinia-related kinase (VRK) proteins are a new family with three members in the human kinome. The
VRK1
protein phosphorylates several transcription factors and has been postulated to be involved in regulation of cell proliferation. In normal squamous epithelium,
VRK1
is expressed in the proliferation area. Because
VRK1
can stabilize p53, the expression of the
VRK1
protein was analyzed in the context of the p53 pathway and the proliferation phenotype in a series of 73 head and neck squamous cell carcinomas.
VRK1
protein level positively correlated with p53 response proteins, particularly hdm2 and p21. The
VRK1
protein also correlated positively with several proteins associated with proliferation, such as cyclin-dependent kinase 2 (CDK2), CDK6, cdc2, cyclins B1 and A,
topoisomerase
II, survivin, and Ki67. The level of
VRK1
protein behaves like a proliferation marker in this series of head and neck squamous cell carcinomas. To identify a possible regulatory role for
VRK1
and because it regulates gene transcription, the promoters of two genes were studied, CDK2 and SURVIVIN, whose proteins correlated positively with
VRK1
.
VRK1
increases the activity of both the CDK2 and SURVIVIN gene promoters. The expression of
VRK1
was analyzed in the context of regulators of the G1-S transition.
VRK1
protein levels increase in response to E2F1 and are reduced by retinoblastoma and p16. These data suggest that
VRK1
might play a role in cell cycle regulation and is likely to represent the beginning of a new control mechanism of cell cycle, particularly late in the G1-S phase.
...
PMID:VRK1 signaling pathway in the context of the proliferation phenotype in head and neck squamous cell carcinoma. 1654 55